We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Seegene

Seegene, Inc. is a developer of multiplex molecular technologies and multiplex clinical molecular diagnostics for inf... read more Featured Products: More products

Download Mobile App





Seegene Highlights High-Throughput, Single Tube 8-Plex RT-PCR Test for Flu A, Flu B, RSV and COVID-19 with Dual Internal Controls

By LabMedica International staff writers
Posted on 16 Dec 2020
Seegene, Inc. More...
(Seoul, Korea) highlighted its new high-throughput 8-plex test for Flu A, Flu B, RSV and COVID-19 with dual internal controls at the all virtual 2020 AACC Annual Scientific Meeting held on December 13-17.

Attendees of the 2020 AACC Virtual Meeting Platform viewed Seegene’s Allplex SARS-CoV-2/FluA/FluB/RSV Assay, a single tube real-time RT-PCR assay that simultaneously detects and differentiates Flu A, Flu B, RSV A/B, and three different target genes of COVID-19 (S gene, RdRP gene and N gene).

Given the similarity in terms of symptoms between seasonal flu and SARS-CoV-2, multiplexing capability will be a critical consideration to accommodate high volume testing necessary for effective disease control in preparation for flu season during COVID-19 pandemic. Seegene's assay incorporates its proprietary high multiplex chemistry technologies, maximizing sensitivity and specificity during PCR amplification and detection of multiple targets. Combined with its unique task target automated system and interpretation software solution, the company offers unparalleled capacity at the most competitive pricing available on the market.

The assay also includes dual targets for internal control (exogenous and endogenous, respectively) run in the same reaction tube, which allow verification of the whole test process as well as proper sampling. The assay is currently validated with a wide range of extraction systems (Seegene STARlet, Seegene NIMBUS, Microlab STARlet IVD, Microlab NIMBUS, Seeprep32, KingFisher Flex, MagNA Pure 96, NucliSENS EasyMag, GeneAll Ribospin vRD Viral RNA/DNA Extraction Kit, QIAamp DSP Viral RNA Mini kit) and plans to expand further upon market demand. For PCR instruments, Bio-Rad CFX96 systems can be used.

Seegene also offered a glimpse of its comprehensive syndromic product portfolio on the same automated solution, including its well-established syndromic respiratory virus/bacteria panels which simultaneously detect 26 different targets.



Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
POC Immunoassay Analyzer
Procise DX
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Graphical Abstract (Morgane Fournier et al., Cell (2026). DOI: 10.1016/j.cell.2026.04.013)

Study Reveals Immune Mechanism Driving Severe COVID-19 Progression

Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more

Pathology

view channel
Image: Agilent’s PD-L1 IHC 22C3 pharmDx has received EU certification as a companion diagnostic to identify PD-L1–positive ovarian, fallopian tube, or primary peritoneal carcinoma patients eligible for KEYTRUDA (Photo courtesy of Agilent)

PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers

Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.